1) Strong Financial Performance
- ResMed reported Q4 revenue of $1.5 billion, reflecting a 9% increase YoY, or 8% on a constant-currency basis.
- Non-GAAP earnings per share (EPS) grew by 16% to $2.95.
- For FY 2026, total revenue grew 10% YoY, with non-GAAP EPS increasing by 17%.
- Free cash flow for the quarter was $404 million, down 21% YoY, primarily due to a $42 million provision related to the Astral device recall.

2) Strategic Focus and Operational Excellence
- ResMed's strategy for FY 2027 emphasizes operational excellence, innovation, and active portfolio management.
- The company is focusing on expanding its digital health ecosystem, particularly in sleep health and breathing health.
- Partnerships, such as with Oura, aim to enhance sleep health awareness and intervention.
- The company is also integrating the Noctrix acquisition to expand its product offerings in sleep disorders.

3) Challenges and Headwinds
- A significant headwind for FY 2027 is the $75 million revenue impact from suspending sales of the Astral devices due to a field safety notice.
- Life support device revenue saw a 45% decline in The Americas, contributing to overall challenges in that segment.
- Inflationary pressures are impacting gross margins, with a 90 basis point increase YoY but a 50 basis point decline sequentially from Q3 to Q4.

4) Product Innovations and Market Expansion
- The AirSense 11 continues to be a key product, with ongoing global rollout and enhancements in patient engagement through digital platforms.
- New product launches, including the AirCurve 11 and novel fabric technology masks, are expected to drive future growth.
- ResMed is committed to continuous innovation, with increased R&D spending by 22% YoY to support next-gen devices and AI-driven solutions.

5) Guidance and Outlook
- For FY 2027, ResMed expects revenue growth in the range of 5% to 7%, with non-GAAP EPS guidance of $12 to $12.25.
- The company plans to return over $1.85 billion to shareholders through dividends and share repurchases, marking a 75% increase YoY.
- The guidance reflects ongoing challenges from the Astral device situation but anticipates strong underlying growth in core sleep devices and masks.

Bottom line: ResMed is positioned for continued growth despite headwinds from the Astral device recall and inflationary pressures. With a strong focus on innovation and operational excellence, the company aims to leverage its market leadership in sleep health to drive shareholder value in FY 2027 and beyond.